Ultivue Announces New Innovation Team Leadership
Ultivue is thrilled to announce the addition of Professor Je Hyuk Lee in the role of Director of Research and Innovation, as the company adds to its growing expertise in spatial biology.
Je Lee is a highly published MD/PhD with over 25 years of scientific experience, most recently leading a successful research group at Cold Spring Harbor Laboratories (CSHL) that focused on innovative imaging and molecular sequencing methods for tracking genes, molecules, and cells to understand how cancer cells arise and evolve. Prior to his tenure at CSHL, Je was at scientist at the Wyss Institute for Biologically Inspired Engineering in Boston and spent many years as a postdoctoral research fellow under Professor George Church at Harvard Medical School, Boston where his highly cited work on the generation and in situ sequencing of whole transcriptome libraries has been seminal to how we consider highly multiplexed and spatially resolved techniques today.
Je holds a BS. Biochemistry from University of Pennsylvania, Philadelphia and a MD, PhD in Cell & Molecular Physiology Tufts School of Medicine, Boston.
Je joins Ultivue after a successful 2021 year of funding and looks to help strengthen its position as a market leader affording innovative solutions for multiplex immunofluorescence and digital image analysis.
"Translating advances in spatial biology into a robust and scalable solution that meets the needs of clinicians and patients is a challenge. Ultivue scientists have developed a deceptively simple solution to that problem, and I look forward to leading the team toward a more practical yet information-rich tissue imaging platform in oncology and research." said Je Lee, adding that “Its exciting to be part of one of the top spatial biology companies in the world today, selected by GEN , a field that has made its way into the mainstream of science when it was unanimously recognized in January 2021 by editors of the Nature journal as Method of the Year 2020”.
“Je Lee is joining at a very exciting time as we continue to accelerate not only our growth in the immuno-oncology market but also how we evolve and think about the future of multi-omics applications, imaging, and the rich amount of information we can gather from spatial phenomics” noted Jacques Corriveau, President and CEO.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005340/en/
Contact information
Ultivue
Jacques Corriveau
President and CEO
Jacques.corriveau@ultivue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 18:12:00 EET | Press release
Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors, EIB’s development arm EIB Global commits €50m, while Proparco will commit €20m and British International Investment has received approval for a €10m commitment, subject to final negotiations. Averrhoa NBS is a SFDR1 Article 9 impact fund overseen by Ardian’s Infrastructure team in partnership with aDryada, a specialist developer and manager of large-scale ecosystem restoration projects. The strategy is dedicated to investing in projects to reforest and restore wetlands and mangroves, intended to protect biodiversity while enab
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 17:00:00 EET | Press release
ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes. The zero-footprint, web-based system performs automated aneurysm segmentation, centerline extraction, precise diameter and angulation measurements
Andersen Consulting Collaborates with TruScore12.11.2025 16:30:00 EET | Press release
Andersen Consulting announces a Collaboration Agreement with TruScore, enhancing its human capital offering to help clients build stronger leadership teams and organizational cultures. Headquartered in the U.S., TruScore specializes in delivering fully customized survey hosting solutions that empower organizations to run scalable, secure, white-label assessment programs tailored to their unique needs. Providing bespoke 360-degree feedback solutions, TruScore works with Fortune 500 corporations, leadership development companies, and independent coaches to design and manage their own proprietary assessment experiences. “In today’s dynamic business environment, organizations need more than just strategy—they need strong, resilient leadership to execute that strategy successfully,” said Derek Murphy, CEO of TruScore. “Through this collaboration with Andersen Consulting, we can bring our assessment and development expertise to a broader audience, helping clients identify and cultivate the l
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 202512.11.2025 16:30:00 EET | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112742665/en/ “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “We look forward to sharing encore data from our Phase 3 MOTION study of vimseltinib and providing updates on our DCC-3009 Phase 1 program, which demonstrate how we can expand our GIST treatment capabilities by t
Deskpro Launches New Private Help Desk Solution with Private AI Support for Organizations with Strict Security, Compliance, and Data Sovereignty Requirements12.11.2025 16:13:00 EET | Press release
Today, Deskpro, provider of the secure AI-powered help desk platform, announced the launch of Deskpro Private, making AI-powered help desk capabilities available to industries with stringent security and compliance requirements for the first time. The new platform delivers flexible private deployment, allowing companies to run their AI-powered help desk entirely within their AWS Virtual Private Cloud (VPC), on-premise enterprise data center, or sovereign cloud. Enterprises can connect to their AI of choice, including commercial, public, private, custom, and open source models, using existing organizational accounts and APIs. This means sensitive data never leaves the organization’s approved security perimeter. With Deskpro, organizations no longer need to sacrifice the measurable ROI from AI capabilities for data security, compliance, or data sovereignty. Deskpro Makes Enterprise-Grade AI Support Possible for Compliance-Bound Teams While many enterprises have experimented and integrate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom